EUCTR2013-005343-82-GB进行中（未招募）1 期
An Expanded Access Protocol for Idelalisib in Combination with Rituximab for Relapsed, Previously Treated Subjects with Chronic Lymphocytic Leukemia
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 31
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •1) Male or female =18 years of age with a diagnosis of B-cell CLL established according to the International Workshop on Chronic Lymphocytic Leukemia (IWCLL) criteria.
- •2) CLL that warrants treatment (consistent with accepted IWCLL criteria for initiation of therapy).
- •3) Prior treatment for CLL comprising any of the following:
- •a) Prior treatment with =1 regimen containing a therapeutic anti-CD20 antibody or
- •b) Prior treatment with =2 regimens containing =1 cytotoxic agent
- •4) CLL progression <24 months since the completion of the last prior therapy for CLL.
- •5) Appropriate for non-cytotoxic-containing therapy based on the presence of any of the following factors:
- •a) Grade =3 neutropenia or thrombocytopenia attributable to cumulative myelotoxicity from prior administration of
- •cytotoxic agents (as documented by bone marrow biopsy obtained since last prior therapy), or
- •b) Estimated creatinine clearance (eCCr) <60 mL/min (as determined by the Cockcroft-Gault method), or
- •c) A Cumulative Illness Rating Scale (CIRS) score of >6
- •6) A negative serum pregnancy test for female subjects of child bearing potential
- •7) Male and female subjects of childbearing potential who engage in heterosexual intercourse must agree to use protocol specified method(s) of contraception.
- •8) Lactating females must agree to discontinue nursing before the IMP is administered.
- •9) Evidence of a personally signed informed consent.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 30
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 120
排除标准
- •1) Known hypersensitivity to the IMP, the metabolites, or formulation excipient.
- •2) Known histological transformation from CLL to an aggressive lymphoma (i.e., Richter transformation).
- •3) Known myelodysplastic syndrome.
- •4) Evidence of ongoing systemic bacterial, fungal, or viral infection at the time of randomization.
- •5) Ongoing drug-induced liver injury, chronic active hepatitis C (HCV), chronic active hepatitis B (HBV), alcoholic liver disease, non-alcoholic steatohepatitis, primary biliary cirrhosis, extrahepatic obstruction caused by cholelithiasis, cirrhosis of the liver, or portal hypertension.
- •6) Ongoing drug-induced pneumonitis.
- •7) Ongoing inflammatory bowel disease.
- •8) History of anaphylaxis in association with previous administration of monoclonal antibodies.
研究者
相似试验
进行中（未招募）
1 期
A study to provide access to idelalisib in combination with rituximab for the treatment of previously treated chronic lymphocytic leukemiaEUCTR2013-005343-82-IEGilead Sciences, Inc.150
进行中（未招募）
不适用
A study to provide access to idelalisib in combination with rituximab for the treatment of previously treated chronic lymphocytic leukemiaChronic lymphocytic leukemiaMedDRA version: 16.1Level: LLTClassification code 10068919Term: B-cell chronic lymphocytic leukemiaSystem Organ Class: 100000004864EUCTR2013-005343-82-DEGilead Sciences, Inc.150
进行中（未招募）
1 期
A study to provide access to idelalisib in combination with rituximab for the treatment of previously treated chronic lymphocytic leukemiaEUCTR2013-005343-82-ITGilead Sciences, Inc.150
Approved For Marketing
不适用
Expanded Access for Idelalisib in Combination With Rituximab in Chronic Lymphocytic LeukemiaChronic Lymphocytic Leukemia (CLL)NCT02136511Gilead Sciences
进行中（未招募）
1 期
This expanded access protocol will provide access to abrocitinib until it becomes commercially available to patientsModerate to severe atopic dermatitis (AD)MedDRA version: 21.1Level: LLTClassification code 10003639Term: Atopic dermatitisSystem Organ Class: 100000004858EUCTR2020-003610-12-GRPfizer Inc.460